ClinicalTrials.gg
TerminatedNCT04605094Updated Aug 31, 2023Results posted

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of Benralizumab and Placebo / Benralizumab in Atopic Dermatitis, sponsored by AstraZeneca. Terminated at 51 sites in 8 countries. Open to participants aged 12 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was terminated
The study did not meet the primary endpoint.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
12 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
181st of 544
194 · median 96
Started
2020
with 36 others
Phase 2
202 of 639
18 open now
Registered
388th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 181st largest by enrollment of the 544 interventional ones that give a count, is one of 37 that started in 2020, is one of 202 in phase 2, and was the 388th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.

Read the detailed description

The aim of this study is to investigate the use of benralizumab as treatment for patients with moderate to severe atopic dermatitis (AD) who remain symptomatic despite treatment with topical medications. It is proposed that benralizumab will deplete eosinophils from affected skin, improve symptoms of AD, and improve AD-related quality of life. This Phase 2 study is designed to compare the efficacy of treatment with benralizumab versus placebo and compare benralizumab maintenance dosing regimens in the extension period.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Moderate to severe atopic dermatitis
  • pruritus
  • skin lesion
04

Who can participate

Ages eligible
12 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Physician-confirmed diagnosis of AD (according to American Academy of Dermatology Consensus Criteria) that is not adequately controlled with topical medications.
  2. EASI score of ≥ 12 at screening and ≥ 16 at randomization.
  3. IGA score of ≥ 3 (on a scale of 0 to 4, in which 3 is moderate and 4 is severe) at screening and at randomization.
  4. Atopic dermatitis involvement of ≥ 8% body- surface area at screening and ≥ 10% body-surface area at randomization.
  5. A pruritus numerical rating scale average score for maximum itch intensity of ≥ 4, based on the average of daily pruritus numerical rating scale scores for maximum itch intensity reported during the 7 days prior to randomization.
  6. Documented recent history (within 6 months prior to screening) of inadequate response to treatment with topical medications, or patients for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks).
  7. Participants that have applied a stable dose of topical emollient (moisturizer) twice daily for ≥ 7 consecutive days immediately before the randomization visit. (NOTE: See exclusion criterion 11 for limitations regarding emollients)
  8. Participants must be willing and able to complete daily PRO assessments:

    • Complete at least 70% of daily PRO assessments between Visit 1 and Visit 2 and
    • Complete at least 5 of 7 daily PRO assessments in the 7 days prior to Visit 2.
  9. Females of (FOCBP) must agree to use a highly effective method of (confirmed by the Investigator) from randomization, throughout the study duration, and within 16 weeks after last dose of IP and have a negative serum pregnancy test result on Visit 1.
  10. Females not of childbearing potential are defined as females who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are . Females will be considered postmenopausal if they have been amenorrheic for ≥ 12 months prior to the planned date of randomization without an alternative medical cause. The following age-specific requirements apply:

    1. Females \< 50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and with follicle-stimulating hormone (FSH) levels in the postmenopausal range. Until FSH is documented to be within menopausal range, the participant should be treated as a FOCBP.
    2. Females ≥ 50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.

Exclusion criteria

Exclusion Criteria:

  1. Participants with active dermatological conditions (eg, psoriasis, seborrheic dermatitis, cutaneous lymphoma) other than atopic dermatitis that, in the investigator's opinion, may interfere with the study assessments
  2. Known active allergic or irritant contact dermatitis that, in the investigator's opinion, may interfere with the study assessments
  3. Current , or history of malignancy, with the exception of:

    1. Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to the date , was obtained.
    2. Participants who have had other malignancies are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to the date informed consent, was obtained.
  4. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    1. Affect the safety of the participant throughout the study
    2. Influence the findings of the studies or their interpretations
    3. Impede the participant's ability to complete the entire duration of study.
  5. History of anaphylaxis to any biologic therapy or vaccine
  6. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy
  7. Any abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening/run-in period which, in the opinion of the Investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete entire duration of the study
  8. Current active liver disease:

    1. Chronic stable and C (including positive testing for hepatitis B surface antigen [HBsAg] or antibody), or other stable chronic liver disease are acceptable if participant otherwise meets eligibility criteria. Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice, or cirrhosis.
    2. (ALT) or aspartate aminotransferase (AST) level ≥ 3 times the (ULN), confirmed by repeated testing during the run-in period. Transient increase of AST/ALT level that resolves by the time of randomization is acceptable if in the Investigator's opinion the participant does not have an active liver disease and meets other eligibility criteria.
  9. A history of known immunodeficiency disorder including a positive (HIV) test Prior/concomitant Therapy
  10. Participants who have received treatment for AD with TCS, topical calcineurin inhibitors (TCI), or topical phosphodiesterase-4 (PDE4) inhibitors within the 7 days prior to the randomization visit
  11. Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (patients may continue using stable doses of such moisturizers if initiated before the screening visit)
  12. Regular use (2 visits per week) of a tanning booth/parlor or phototherapy for AD within 4 weeks prior to the randomization visit
  13. Use of medication including, but not limited to: methotrexate, cyclosporine, azathioprine, systemic within 4 weeks or 5 half-lives prior to the date informed consent is obtained, whichever is longer.

    Other

  14. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained
  15. Receipt of any marketed or biologic within 4 months or 5 half-lives prior to the date informed consent is obtained, whichever is longer
  16. Receipt of 30 days prior to first dose of IP
  17. Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to the date informed consent is obtained, whichever is longer
  18. Previously received benralizumab (MEDI-563, FASENRA)
  19. Change to allergen immunotherapy or new allergen immunotherapy within 30 days prior to the date of informed consent and anticipated changes in immunotherapy throughout the study
  20. Planned elective major surgical procedures during the conduct of the study
  21. Previous randomization in the present study
  22. Concurrent enrollment in another clinical trial
  23. AstraZeneca staff involved in the planning and/or conduct of the study
  24. For females only: Currently pregnant, breastfeeding, or lactating females A serum pregnancy test will be done for FOCBP at Visit 1 and a urine pregnancy test must be performed for FOCBP at each subsequent treatment visit prior to IP administration. A positive urine test result must be confirmed with a serum pregnancy test. If serum test is positive, the participant should be excluded.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Biological: Benralizumab

  • Experimental
    Placebo / Benralizumab

    Biological: Placebo / Benralizumab

Interventions

  • BiologicalBenralizumab

    Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.

    Also known as: Benralizumab, Benra, Fasenra

  • BiologicalPlacebo / Benralizumab

    Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.

    Also known as: Benralizumab, Benra, Fasenra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Investigator Global Assessment (IGA) 0/1 and a Decrease in IGA of ≥2 Points at Week 16 Relative to Baseline

    The IGA is an instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 = clear; 1 = almost clear; 2 = mild disease; 3 = moderate disease; 4 = severe disease. The IGA used clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines for the overall severity assessment. A higher score indicated greater severity. A responder at Week 16 was defined as having IGA 0/1 and a decrease in IGA of ≥2 points at Week 16 relative to baseline. Participants who withdrew from the study/required rescue therapy after Day 28 were considered as non-responders from the time these events occurred. Baseline was defined as the last recorded value on or prior to the date of randomization.

    Time frame: Baseline (Week 0) and at Week 16

Secondary outcomes

  1. Percentage of Participants Who Experienced 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16

    The EASI assessed the severity and extent of AD. Severity of 4 AD disease characteristics (erythema, induration/papulation, excoriation \[scratching\], lichenification) each were assessed on a scale of 0 (absent) to 3 (severe) in each of 4 body regions (head/neck, trunk, upper limbs, and lower limbs). Total body total score=sum of the region total scores; ranged from 0 to 72. Participants were classified as responders if they achieved at least 75% reduction from baseline in their EASI total score at Week 16. Participants who withdrew from study/required rescue therapy after Day 28 were non-responders from the time these events occurred. Higher scores indicated a more severe or more extensive condition. Baseline was defined as the last recorded value on or prior to the date of randomization.

    Time frame: Baseline (Week 0) and at Week 16

  2. Percentage of Participants Who Experienced 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16

    The EASI assessed the severity and extent of AD. Severity of 4 AD disease characteristics (erythema, induration/papulation, excoriation \[scratching\], lichenification) each were assessed on a scale of 0 (absent) to 3 (severe) in each of 4 body regions (head/neck, trunk, upper limbs, and lower limbs). Total body total score=sum of the region total scores; ranged from 0 to 72. Participants were classified as responders if they achieved at least 90% reduction from baseline in their EASI total score at Week 16. Participants who withdrew from study/required rescue therapy after Day 28 were non-responders from the time these events occurred. Higher scores indicated a more severe or more extensive condition. Baseline was defined as the last recorded value on or prior to the date of randomization.

    Time frame: Baseline (Week 0) and at Week 16

  3. Percentage of Participants With an Improvement of ≥4 or More Points in Peak Pruritus Weekly Score

    The peak pruritus numeric rating scale (NRS) was a 1-item daily assessment of the worst itch the participant experienced over the past 24 hours. The score ranged from 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable" and so a reduction in score was considered an improvement. A responder was defined as having an improvement of 4 or more points relative to baseline. Participants who withdrew from the study/required rescue therapy after Day 28 were considered as non-responders from the time these events occurred. The Week 16 weekly scores were defined as the average of the daily scores for the 7 days prior to the weekly score.

    Time frame: At Week 16

07

Results

Posted Jun 27, 2023
Limitations and caveats
The study was terminated as the study did not support the continued development of benralizumab for the indication of AD.

Participant flow

This Phase 2, double-blind, placebo-controlled study was conducted in participants with moderate to severe atopic dermatitis (AD) at 48 study centers in 8 countries.

Participant flow — Overall Study
MilestoneBenralizumabPlacebo
Started9698
Completed3737
Not completed5961
Withdrew: Adverse event22
Withdrew: Lost to follow-up14
Withdrew: Physician decision22
Withdrew: Study terminated by sponsor3133
Withdrew: Withdrawal by subject2219
Withdrew: Other11

Outcome measures

PrimaryPercentage of Participants With an Investigator Global Assessment (IGA) 0/1 and a Decrease in IGA of ≥2 Points at Week 16 Relative to Baseline

The IGA is an instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 = clear; 1 = almost clear; 2 = mild disease; 3 = moderate disease; 4 = severe disease. The IGA used clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines for the overall severity assessment. A higher score indicated greater severity. A responder at Week 16 was defined as having IGA 0/1 and a decrease in IGA of ≥2 points at Week 16 relative to baseline. Participants who withdrew from the study/required rescue therapy after Day 28 were considered as non-responders from the time these events occurred. Baseline was defined as the last recorded value on or prior to the date of randomization.

Time frame:
Baseline (Week 0) and at Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator Global Assessment (IGA) 0/1 and a Decrease in IGA of ≥2 Points at Week 16 Relative to Baseline
percentage of participantsBenralizumabPlacebo
Percentage of Participants With an Investigator Global Assessment (IGA) 0/1 and a Decrease in IGA of ≥2 Points at Week 16 Relative to Baseline9.4 (3.36 to 14.93)17.3 (10.40 to 25.12)
Statistical analysis
  • Benralizumab vs Placebo · Regression, Logistic · p = 0.080 · Difference in response rate: -8.62 · 95% CI -17.94 to 0.71
SecondaryPercentage of Participants Who Experienced 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16

The EASI assessed the severity and extent of AD. Severity of 4 AD disease characteristics (erythema, induration/papulation, excoriation \[scratching\], lichenification) each were assessed on a scale of 0 (absent) to 3 (severe) in each of 4 body regions (head/neck, trunk, upper limbs, and lower limbs). Total body total score=sum of the region total scores; ranged from 0 to 72. Participants were classified as responders if they achieved at least 75% reduction from baseline in their EASI total score at Week 16. Participants who withdrew from study/required rescue therapy after Day 28 were non-responders from the time these events occurred. Higher scores indicated a more severe or more extensive condition. Baseline was defined as the last recorded value on or prior to the date of randomization.

Time frame:
Baseline (Week 0) and at Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16
percentage of participantsBenralizumabPlacebo
Percentage of Participants Who Experienced 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 1619.8 (11.71 to 27.45)24.5 (16.27 to 33.19)
Statistical analysis
  • Benralizumab vs Placebo · Regression, Logistic · p = 0.384 · Difference in response rate: -5.15 · 95% CI -16.67 to 6.36
SecondaryPercentage of Participants Who Experienced 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16

The EASI assessed the severity and extent of AD. Severity of 4 AD disease characteristics (erythema, induration/papulation, excoriation \[scratching\], lichenification) each were assessed on a scale of 0 (absent) to 3 (severe) in each of 4 body regions (head/neck, trunk, upper limbs, and lower limbs). Total body total score=sum of the region total scores; ranged from 0 to 72. Participants were classified as responders if they achieved at least 90% reduction from baseline in their EASI total score at Week 16. Participants who withdrew from study/required rescue therapy after Day 28 were non-responders from the time these events occurred. Higher scores indicated a more severe or more extensive condition. Baseline was defined as the last recorded value on or prior to the date of randomization.

Time frame:
Baseline (Week 0) and at Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16
percentage of participantsBenralizumabPlacebo
Percentage of Participants Who Experienced 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 167.3 (2.05 to 12.42)15.3 (8.33 to 22.50)
Statistical analysis
  • Benralizumab vs Placebo · Regression, Logistic · p = 0.078 · Difference in response rate: -8.18 · 95% CI -16.94 to 0.59
SecondaryPercentage of Participants With an Improvement of ≥4 or More Points in Peak Pruritus Weekly Score

The peak pruritus numeric rating scale (NRS) was a 1-item daily assessment of the worst itch the participant experienced over the past 24 hours. The score ranged from 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable" and so a reduction in score was considered an improvement. A responder was defined as having an improvement of 4 or more points relative to baseline. Participants who withdrew from the study/required rescue therapy after Day 28 were considered as non-responders from the time these events occurred. The Week 16 weekly scores were defined as the average of the daily scores for the 7 days prior to the weekly score.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Improvement of ≥4 or More Points in Peak Pruritus Weekly Score
percentage of participantsBenralizumabPlacebo
Percentage of Participants With an Improvement of ≥4 or More Points in Peak Pruritus Weekly Score14.6 (7.87 to 21.70)14.3 (7.28 to 20.90)
Statistical analysis
  • Benralizumab vs Placebo · Regression, Logistic · p = 0.889 · Difference in response rate: 0.69 · 95% CI -8.93 to 10.32

Adverse events

Collected over Adverse events in the on-study period were reported from the first dose of study treatment (Day 1) up to end of follow-up, approximately a maximum up to Week 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab0/96 (0%)3/96 (3.1%)38/96 (39.6%)
Placebo0/98 (0%)0/98 (0%)10/98 (10.2%)
Placebo to Benralizumab0/87 (0%)2/87 (2.3%)29/87 (33.3%)
Most frequent serious events
Most frequent serious events
EventBenralizumabPlaceboPlacebo to Benralizumab
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/960/981/87
MigraineNervous system disorders0/960/981/87
Cardiac failure congestiveCardiac disorders1/960/980/87
Paranasal sinus inflammationRespiratory, thoracic and mediastinal disorders1/960/980/87
Dermatitis atopicSkin and subcutaneous tissue disorders1/960/980/87
Most frequent other events
Most frequent other events
EventBenralizumabPlaceboPlacebo to Benralizumab
COVID-19Infections and infestations21/964/9814/87
NasopharyngitisInfections and infestations9/960/987/87
Upper respiratory tract infectionInfections and infestations9/962/985/87
ConjunctivitisInfections and infestations3/960/986/87
BronchitisInfections and infestations5/960/984/87
HeadacheNervous system disorders4/965/980/87

Baseline characteristics

The Full Analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study drug, irrespective of their protocol adherence and continued participation in the study.

Age, Continuous
Age, Continuous(years)BenralizumabPlaceboTotal
Mean29.8 ± 15.8729.5 ± 16.0029.6 ± 15.90
Sex: Female, Male
Sex: Female, Male(Participants)BenralizumabPlaceboTotal
Female403272
Male5666122
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BenralizumabPlaceboTotal
Black or African American6612
Asian242044
White6570135
Other123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BenralizumabPlaceboTotal
Hispanic or Latino111324
Not Hispanic or Latino8585170
08

Study locations

51 sites
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Bridgeport, Connecticut 06606, United States
  • Research Site
    Fort Myers, Florida 33912, United States
  • Research Site
    Tampa, Florida 33606, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Ypsilanti, Michigan 48197, United States
  • Research Site
    Portsmouth, New Hampshire 03801, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Rochester, New York 14620, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Norman, Oklahoma 73071, United States
  • Research Site
    Sugarloaf, Pennsylvania 18249, United States
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Parkville, 3050, Australia
  • Research Site
    Sippy Downs, 4556, Australia
  • Research Site
    Woolloongabba, 04102, Australia
  • Research Site
    Haskovo, 6300, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Sofia, 1000, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Brno, 602 00, Czechia
  • Research Site
    Ostrava-Poruba, 708 52, Czechia
  • Research Site
    Ostrava, 702 00, Czechia
  • Research Site
    Pardubice, 530 02, Czechia
  • Research Site
    Praha 10, 100 00, Czechia
  • Research Site
    Praha, 110 00, Czechia
  • Research Site
    Brest Cedex 2, 29609, France
  • Research Site
    Lille Cedex, 59037, France
  • Research Site
    Ansan-si, 15355, Korea, Republic of
  • Research Site
    Daegu, 41944, Korea, Republic of
  • Research Site
    Gwangju, 61453, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 04763, Korea, Republic of
  • Research Site
    Seoul, 05278, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 06973, Korea, Republic of
  • Research Site
    Seoul, 07441, Korea, Republic of
  • Research Site
    Seoul, 5030, Korea, Republic of
  • Research Site
    Yangsan-si, 50612, Korea, Republic of
  • Research Site
    Krakow, 30-033, Poland
  • Research Site
    Lodz, 90-302, Poland
  • Research Site
    Osielsko, 86031, Poland
  • Research Site
    Poznań, 60-214, Poland
  • Research Site
    Warszawa, 01-262, Poland
  • Research Site
    Alicante, 03010, Spain
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Cordoba, 14004, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Manises, 46940, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Apr 2022, 17 months.

Results were first posted in Jun 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Oct 27, 2020
StartActual
Nov 12, 2020
Primary completionActual
Apr 25, 2022
CompletionActual
Sep 13, 2022
Results first posted
Jun 27, 2023
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04605094
Lead sponsor
AstraZeneca
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Nov 12, 2020
Primary completion
Apr 25, 2022
Completion
Sep 13, 2022
Results posted
Jun 27, 2023
Last update
Aug 31, 2023

Study contacts

Emma Guttman, MD, PhD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion